Notably, we have shown that the expression levels of IL-1β in the primary tumours of breast cancer patients were significantly associated with their brain metastatic statuses, suggesting that IL-1β may serve as a potential prognostic marker and a therapeutic target for brain metastasis. This evidence concerns the gene IL1B and breast cancer.